

1 Article

2 **The first Catalytic Direct C-H arylation on C2 and C3**
3 **of thiophene ring applied to thieno-pyridines, -**
4 **pyrimidines and –pyrazines**

5 **Joana F. Campos^{1,2}, Maria-João R. P. Queiroz² and Sabine Berteina-Raboin^{1,*}**

6 ¹ Institut de Chimie Organique et Analytique (ICOA), Université d'Orléans UMR-CNRS 7311, BP 6759, rue
7 de Chartres 45067 Orléans cedex 2, France

8 ² Departamento/Centro de Química, Escola de Ciências, Universidade do Minho, Campus de Gualtar, 4710-
9 057 Braga, Portugal

10 * Correspondence: sabine.berteina-raboin@univ-orleans.fr; Tel.: +33-238-494-856

11 Received: date; Accepted: date; Published: date

12

13

14

15

16

17

18

Experimental Section

19

1. <i>Materials and Methods</i>	2
1.1. <i>General Methods</i>	2
1.2. <i>General procedure for synthesis of all Products</i>	2-8
1.3. <i>¹H NMR, ¹³C NMR and ¹⁹F NMR Spectra of all Products</i>	9-35
1.4. <i>References</i>	36

20

21

22

23

24

25

26

27

28

29

30

31

32

33

34 1. Materials and Methods

35 1.1. General Methods

36 All reagents were purchased from commercial suppliers and were used without further
37 purification. THF was dried with a dry station GT S100 instantaneously prior to use. The reactions
38 were monitored by thin-layer chromatography (TLC) analysis using silica gel (60 F254) plates.
39 Compounds were visualized by UV irradiation. Flash column chromatography was performed on
40 silica gel 60 (230 - 400 mesh, 0.040 - 0.063 mm). Melting points (mp [°C]) were taken on samples in
41 open capillary tubes and are uncorrected. The infrared spectra of compounds were recorded on a
42 Thermo Scientific Nicolet iS10. ¹H and ¹³C NMR spectra were recorded on a Bruker avance II
43 spectrometer at 250 MHz (¹³C, 62.9 MHz) and on a Bruker avance III HD nanobay 400 MHz (¹³C 100.62
44 MHz). Chemical shifts are given in parts per million from tetramethylsilane (TMS) or deterrred solvent
45 (MeOH-*d*₄, Chloroform-*d*) as internal standard. The following abbreviations are used for the proton
46 spectra multiplicities: b : broad, s: singlet, d: doublet, t: triplet, q: quartet, p: pentuplet, m: multiplet.
47 Coupling constants (*J*) are reported in Hertz (Hz). High-resolution mass spectra (HRMS (ESI)) were
48 performed on a Maxis Bruker 4G by the "Federation de Recherche" ICOA/CBM (FR2708) platform.

49 1.2. General procedure for synthesis of thieno[3,2-*d*]pyrimidin-4-amines (7-13)

50 A solution of 4-chlorothieno[3,2-*d*]pyrimidine (**6**) (100 mg; 0.586 mmol) and amine derivative
51 (1.172 mmol) was heated at 100 °C in dry toluene, for 20-30min. The reaction was followed by TLC.
52 After completion, the mixture was concentrated under vacuum. The solid obtained was purified by
53 column chromatography. The solvent polarity was increased via a gradient from neat petroleum
54 ether to a mixture of AcOEt/petroleum ether.

55 4-(thieno[3,2-*d*]pyrimidin-4-yl)morpholine (**7**) [30]

56 From compound **6** (100 mg; 0.586 mmol), morpholine (102 mg; 1.172 mmol) and after purification
57 by column chromatography using a solvent gradient from neat petroleum ether to 50%
58 AcOEt/petroleum ether, compound **7** was obtained as a white solid (111 mg, 86%), m.p. 141 – 143 °C.
59 ¹H NMR (400 MHz, CDCl₃) δ 3.78 – 3.82 (m, 4H), 3.91 – 3.97 (m, 4H), 7.39 (d, *J* = 5.6 Hz, 1H), 7.69 (d, *J*
60 = 5.6 Hz, 1H), 8.56 (s, 1H) ppm. ¹³C NMR (100.6 MHz, CDCl₃) δ 46.3 (2xCH), 66.7 (2xCH), 114.4 (C),
61 125.3 (CH), 131.5 (CH), 154.2 (CH), 158.2 (C), 161.6 (C) ppm.

62 *N,N*-dibutylthieno[3,2-*d*]pyrimidin-4-amine (**8**)

63 From compound **6** (100 mg; 0.586 mmol), di-*n*-butylamine (152 mg; 1.172 mmol) and after
64 purification by column chromatography using a solvent gradient from neat petroleum ether to 40%
65 AcOEt/petroleum ether, compound **8** was obtained as a white solid (148 mg, 96%), m.p. 121 – 123
66 °C. ¹H NMR (400 MHz, CDCl₃) δ 0.92 (t, *J* = 7.4 Hz, 6H), 1.32 – 1.40 (m, 4H), 1.64 (dd, *J* = 6.6, 16.9 Hz,
67 4H), 3.63 – 3.68 (m, 4H), 7.31 (d, *J* = 5.6 Hz, 1H), 7.62 (d, *J* = 5.6 Hz, 1H), 8.45 (s, 1H) ppm. ¹³C NMR
68 (100.6 MHz, CDCl₃) δ 13.9 (2xCH), 20.1 (2xCH), 30.8 (2xCH), 49.3 (2xCH), 113.3 (C), 124.9 (CH), 130.9
69 (CH), 154.3 (CH), 157.5 (C), 160.6 (C) ppm. HRMS: calcd. for C₁₄H₂₂N₃S [M+H]⁺ 264.1529, found
70 264.1532.

71 4-(piperidin-1-yl)thieno[3,2-*d*]pyrimidine (**9**)

72 From compound **6** (100 mg; 0.586 mmol), piperidine (100 mg; 1.172 mmol) and after purification
73 by column chromatography using a solvent gradient from neat petroleum ether to 40%
74 AcOEt/petroleum ether, compound **9** was obtained as a white solid (105 mg, 82%), m.p. 154 – 156 °C.
75 ¹H NMR (400 MHz, CDCl₃) δ 1.10 – 1.61 (m, 6H), 3.87 – 3.90 (m, 4H), 7.33 (d, *J* = 5.6 Hz, 1H), 7.62 (d, *J*
76 = 5.6 Hz, 1H), 8.49 (s, 1H) ppm. ¹³C NMR (100.6 MHz, CDCl₃) δ 24.7 (CH), 26.1 (2xCH), 47.4 (2xCH),

77 114.2 (C), 125.1 (CH), 131.1 (CH), 154.2 (CH), 157.8 (C), 161.0 (C) ppm. CAS: 679394-37-7; SIA
78 Enamine.

79 N-(2-(trifluoromethyl)phenyl)thieno[3,2-d]pyrimidin-4-amine (10)

80 From compound **6** (100 mg; 0.586 mmol), 2-trifluoromethylaniline (189 mg; 1.172 mmol) and
81 after purification by column chromatography using a solvent gradient from neat petroleum ether to
82 40% AcOEt/petroleum ether, compound **10** was obtained as a white solid (104 mg, 60%), m.p. 122 –
83 124 °C. ¹H NMR (400 MHz, CDCl₃) δ 7.37 (t, *J* = 7.7 Hz, 1H), 7.45 (d, *J* = 5.4 Hz, 1H), 7.62 (t, *J* = 7.8 Hz,
84 1H), 7.70 – 7.76 (m, 2H), 7.99 (d, *J* = 8.1 Hz, 1H), 8.70 (s, 1H) ppm. ¹³C NMR (100.6 MHz, CDCl₃) δ
85 122.5 (C), 124.2 (C), 124.5 (C), 125.1 (CH), 126.0 (CH), 126.7 (CH), 127.8 (CH), 132.6 (CH), 132.9 (CH),
86 135.3 (C), 154.5 (CH), 155.9 (C), 161.5 (C) ppm. ¹⁹F NMR (376 MHz, CDCl₃) δ -60.8 ppm. HRMS: calcd.
87 for C₁₃H₉F₃N₃S [M+H]⁺ 296.0464, found 296.0467.

88 N-(4-methoxyphenyl)thieno[3,2-d]pyrimidin-4-amine (11) [31]

89 From compound **6** (100 mg; 0.586 mmol), 4-methoxyaniline (144 mg; 1.172 mmol) and after
90 purification by column chromatography using a solvent gradient from neat petroleum ether to 45%
91 AcOEt/petroleum ether, compound **11** was obtained as a white solid (130 mg, 86%), m.p. 154-156
92 °C. ¹H NMR (400 MHz, CDCl₃) δ 3.85 (s, 3H), 6.92 – 6.96 (m, 2H), 7.36 (d, *J* = 5.4 Hz, 1H), 7.38 – 7.42
93 (m, 2H), 7.64 (d, *J* = 5.4 Hz, 1H), 7.93 (s, 1H), 8.60 (s, 1H) ppm. ¹³C NMR (100.6 MHz, CDCl₃) δ 55.5
94 (CH), 114.3 (2xCH), 114.4 (C), 124.6 (2xCH), 128.2 (CH), 129.7 (C), 133.2 (CH), 154.6 (CH), 157.3 (C),
95 158.6 (C), 161.2 (C) ppm.

96 methyl 4-(thieno[3,2-d]pyrimidin-4-ylamino)benzoate (12)

97 From compound **6** (100 mg; 0.586 mmol), methyl-4-aminobenzoate (177 mg; 1.172 mmol) and
98 after purification by column chromatography using a solvent gradient from neat petroleum ether to
99 45% AcOEt/petroleum ether, compound **12** was obtained as a white solid (111 mg, 67%), m.p. 227 –
100 229 °C. ¹H NMR (400 MHz, CDCl₃) δ 3.93 (s, 3H), 6.97 (d, *J* = 19.8 Hz, 1H), 7.51 (d, *J* = 5.4 Hz, 1H),
101 7.79 – 7.84 (m, 3H), 8.09 (d, *J* = 8.7 Hz, 2H), 8.82 (s, 1H) ppm. ¹³C NMR (100.6 MHz, CDCl₃) δ 29.7 (C),
102 52.1 (CH), 116.2 (C), 120.5 (2xCH), 125.6 (CH), 130.9 (2xCH), 132.1 (CH), 142.4 (C), 154.6 (CH), 154.9
103 (C), 161.2 (C), 166.6 (C) ppm. HRMS: calcd. for C₁₄H₁₂N₃O₂S [M+H]⁺ 286.0645, found 286.0646.

104 N-((3s,5s,7s)-adamantan-1-yl)thieno[3,2-d]pyrimidin-4-amine (13)

105 From compound **6** (100 mg; 0.586 mmol), adamantylamine (177 mg; 1.172 mmol) and after
106 purification by column chromatography using a solvent gradient from neat petroleum ether to 50%
107 AcOEt/petroleum ether, compound **13** was obtained as a white solid (114 mg, 68%), m.p. 238 – 240
108 °C. ¹H NMR (400 MHz, CDCl₃) δ 1.70 – 1.77 (m, 6H), 2.14 (s, 3H), 2.24 (d, *J* = 2.6 Hz, 6H), 4.52 (s, 1H),
109 7.36 (d, *J* = 5.4 Hz, 1H), 7.61 (d, *J* = 5.4 Hz, 1H), 8.57 (s, 1H) ppm. ¹³C NMR (100.6 MHz, CDCl₃) δ 29.6
110 (3xCH), 36.4 (3xCH), 41.9 (3xCH), 53.6 (C), 115.6 (C), 125.6 (CH), 129.7 (CH), 154.6 (CH), 156.9 (C),
111 159.5 (C) ppm. HRMS: calcd. for C₁₆H₂₀N₃S [M+H]⁺ 286.1372, found 286.1375.

112 General procedure for synthesis of 14-23 from 6 (one pot 2 steps “C-2” CH activation)

113 A solution of 4-chlorothieno[3,2-d]pyrimidine (**6**) (100 mg; 0.586 mmol) and morpholine (1.172
114 mmol) was heated at 100 °C in dry toluene, for 20 min. Then, Pd(OAc)₂ (0.059 mmol), TTBP-HBF₄
115 (0.117 mmol), K₂CO₃ (1.172 mmol) and bromo derivative (1.172 mmol) were added. The reaction
116 mixture was stirred at same temperature for 46h. The reaction was followed by TLC. After
117 completion, the mixture was concentrated under vacuum. The solid obtained was purified by column
118 chromatography. The solvent polarity was increased via a gradient from neat petroleum ether to a
119 mixture of AcOEt/petroleum ether.

120 4-(6-phenylthieno[3,2-d]pyrimidin-4-yl)morpholine (14)

121 From compound **6** (100 mg; 0.586 mmol), morpholine (102 mg; 1.172 mmol) followed by
122 Pd(OAc)₂ (13 mg; 0.059 mmol), TTBP · HBF₄ (34 mg; 0.117 mmol), K₂CO₃ (162 mg; 1.172 mmol),
123 bromobenzene (184 mg; 1.172 mmol) and after purification by column chromatography using a
124 solvent gradient from neat petroleum ether to 27% AcOEt/petroleum ether, compound **14** was
125 obtained as a yellow solid (122 mg, 70%), m.p. 149 – 151 °C. ¹H NMR (400 MHz, Chloroform-d) δ 3.86
126 – 3.89 (m, 4H), 3.99 – 4.03 (m, 4H), 7.41 – 7.49 (m, 3H), 7.61 (s, 1H), 7.71 – 7.76 (m, 2H), 8.59 (s, 1H)
127 ppm. ¹³C NMR (100.6 MHz, CDCl₃) δ 46.4 (2xCH), 66.8 (2xCH), 114.2 (C), 120.5 (CH), 126.6 (2xCH),
128 129.2 (2xCH), 129.6 (CH), 132.8 (C), 149.5 (C), 154.5 (CH), 157.9 (C), 162.3 (C) ppm. HRMS: calcd. for
129 C₁₆H₁₆N₃OS [M+H]⁺ 298.1009, found 298.1008.

130 4-(6-(p-tolyl)thieno[3,2-d]pyrimidin-4-yl)morpholine (16)

131 From compound **6** (100 mg; 0.586 mmol), morpholine (102 mg; 1.172 mmol) followed by
132 Pd(OAc)₂ (13 mg; 0.059 mmol), TTBP · HBF₄ (34 mg; 0.117 mmol), K₂CO₃ (162 mg; 1.172 mmol), 4-
133 bromotoluene (200 mg; 1.172 mmol) and after purification by column chromatography using a
134 solvent gradient from neat petroleum ether to 40% AcOEt/petroleum ether, compound **17** was
135 obtained as a white solid (106 mg, 58%), m.p. 144 – 146 °C. ¹H NMR (400 MHz, CDCl₃) δ 8.28 (s, 1H),
136 7.32 (d, *J* = 8.2 Hz, 2H), 6.98 – 6.93 (m, 3H), 3.71 – 3.69 (m, 4H), 3.58 – 3.55 (m, 4H), 2.11 (s, 3H) ppm.
137 ¹³C NMR (100.6 MHz, CDCl₃) δ 162.4 (C), 157.9 (C), 154.5 (CH), 149.7 (C), 139.9 (C), 129.9 (2xCH),
138 126.5 (2xCH), 119.9 (CH), 113.9 (C), 100.0 (C), 66.8 (2xCH), 46.4 (2xCH), 21.4 (CH) ppm. HRMS: calcd.
139 for C₁₇H₁₈N₃OS [M+H]⁺ 312.1165, found 312.1165.

140 4-(6-(3,4,5-trimethoxyphenyl)thieno[3,2-d]pyrimidin-4-yl)morpholine (17)

141 From compound **6** (100 mg; 0.586 mmol), morpholine (102 mg; 1.172 mmol) followed by
142 Pd(OAc)₂ (13 mg; 0.059 mmol), TTBP · HBF₄ (34 mg; 0.117 mmol), K₂CO₃ (162 mg; 1.172 mmol), 5-
143 bromo-1,2,3-trimethoxybenzene (290 mg; 1.172 mmol) and after purification by column
144 chromatography using a solvent gradient from neat petroleum ether to 35% AcOEt/petroleum ether,
145 compound **18** was obtained as a white solid (143 mg, 63%), m.p. 191 – 193 °C. ¹H NMR (400 MHz,
146 CDCl₃) δ 3.86 – 3.89 (m, 4H), 3.90 (s, 3H), 3.95 (s, 6H), 3.99 – 4.02 (m, 4H), 6.91 (s, 2H), 7.53 (s, 1H), 8.59
147 (s, 1H) ppm. ¹³C NMR (100.6 MHz, CDCl₃) δ 46.4 (2xCH), 56.3 (2xCH), 61.0 (CH), 66.8 (2xCH), 104.1
148 (2xCH), 114.0 (C), 120.4 (CH), 128.4 (C), 139.6 (C), 149.5 (C), 153.7 (2xC), 154.5 (CH), 157.8 (C), 162.3
149 (C) ppm. HRMS: calcd for C₁₉H₂₂N₃O₄S [M+H]⁺ 388.1326, found 388.1327.

150 methyl 4-(4-morpholinothieno[3,2-d]pyrimidin-6-yl)benzoate (18)

151 From compound **6** (100 mg; 0.586 mmol), morpholine (102 mg; 1.172 mmol) followed by
152 Pd(OAc)₂ (13 mg; 0.059 mmol), TTBP · HBF₄ (34 mg; 0.117 mmol), K₂CO₃ (162 mg; 1.172 mmol), methyl
153 4-bromobenzoate (252 mg; 1.172 mmol) and after purification by column chromatography using a
154 solvent gradient from neat petroleum ether to 40% AcOEt/petroleum ether, compound **19** was
155 obtained as a yellow solid (127 mg, 61%), m.p. 195 – 197 °C. ¹H NMR (400 MHz, CDCl₃) δ 3.87 (dd, *J*
156 = 4.8, 3.1 Hz, 4H), 3.96 (s, 3H), 4.00 – 4.03 (m, 4H), 7.70 (s, 1H), 7.80 (d, *J* = 8.5 Hz, 2H), 8.12 (d, *J* = 8.5
157 Hz, 2H), 8.61 (s, 1H) ppm. ¹³C NMR (100.6 MHz, CDCl₃) δ 46.4 (2xCH), 52.3 (CH), 66.8 (2xCH), 122.0
158 (CH), 125.3 (C), 126.4 (2xCH), 130.4 (2xCH), 131.5 (C), 136.9 (C), 147.8 (C), 154.2 (C), 154.7 (CH), 157.9
159 (C), 166.4 (C) ppm. HRMS: calcd. for C₁₈H₁₈N₃O₃S [M+H]⁺ 356.1063, found 356.1065.

160 4-(6-(4-ethylphenyl)thieno[3,2-d]pyrimidin-4-yl)morpholine (19)

161 From compound **6** (100 mg; 0.586 mmol), morpholine (102 mg; 1.172 mmol) followed by
162 Pd(OAc)₂ (13 mg; 0.059 mmol), TTBP · HBF₄ (34 mg; 0.117 mmol), K₂CO₃ (162 mg; 1.172 mmol), 1-
163 bromo-4-ethylbenzene (217 mg; 1.172 mmol) and after purification by column chromatography using

164 a solvent gradient from neat petroleum ether to 40% AcOEt/petroleum ether, compound **20** was
165 obtained as a white solid (103 mg, 54%), m.p. 186 – 188 °C. ¹H NMR (400 MHz, CDCl₃) δ 1.29 (d, *J* =
166 7.6 Hz, 3H), 2.68 – 2.73 (m, 2H), 3.86 – 3.89 (m, 4H), 4.00 – 4.04 (m, 4H), 7.29 (d, *J* = 8.2 Hz, 2H), 7.59
167 (s, 1H), 7.65 (d, *J* = 8.2 Hz, 2H), 8.58 (s, 1H) ppm. ¹³C NMR (100.6 MHz, CDCl₃) δ 15.4 (CH), 28.7 (CH),
168 46.5 (2xCH), 66.8 (2xCH), 100.0 (C), 112.1 (C), 119.0 (C), 126.6 (2xCH), 127.6 (CH), 128.7 (2xCH), 130.0
169 (C), 155.3 (CH), 160.1 (C), 173.1 (C) ppm. HRMS: calcd. for C₁₈H₂₀N₃OS [M+H]⁺ 326.1322, found
170 326.1320.

171 4-(6-(benzo[b]thiophen-2-yl)thieno[3,2-d]pyrimidin-4-yl)morpholine (20)

172 From compound **6** (100 mg; 0.586 mmol), morpholine (102 mg; 1.172 mmol) followed by
173 Pd(OAc)₂ (13 mg; 0.059 mmol), TTBP · HBF₄ (34 mg; 0.117 mmol), K₂CO₃ (162 mg; 1.172 mmol), 2-
174 bromobenzothiophene (250 mg; 1.172 mmol) and after purification by column chromatography using
175 a solvent gradient from neat petroleum ether to 55% AcOEt/petroleum ether, compound **21** was
176 obtained as a yellow solid (89 mg, 43%), m.p. 209 – 211 °C. ¹H NMR (400 MHz, CDCl₃) δ 3.87 – 3.89
177 (m, 4H), 3.99 – 4.02 (m, 4H), 7.37 – 7.40 (m, 2H), 7.58 (s, 1H), 7.63 (s, 1H), 7.79 – 7.85 (m, 2H), 8.60 (s,
178 1H) ppm. ¹³C NMR (100.6 MHz, CDCl₃) δ 46.4 (2xCH), 66.8 (2xCH), 114.1 (C), 121.9 (CH), 122.3 (CH),
179 122.6 (CH), 124.2 (CH), 125.1 (CH), 125.7 (CH), 135.4 (C), 139.8 (C), 140.0 (C), 142.4 (C), 154.7 (CH),
180 157.8 (C), 161.9 (C) ppm. HRMS: calcd. for C₁₈H₁₆N₃OS₂ [M+H]⁺ 354.0729, found 354.0731.

181 4-(6-(naphthalen-1-yl)thieno[3,2-d]pyrimidin-4-yl)morpholine (21)

182 From compound **6** (100 mg; 0.586 mmol), morpholine (102 mg; 1.172 mmol) followed by
183 Pd(OAc)₂ (13 mg; 0.059 mmol), TTBP · HBF₄ (34 mg; 0.117 mmol), K₂CO₃ (162 mg; 1.172 mmol), 1-
184 bromonaphthalene (242 mg; 1.172 mmol) and after purification by column chromatography using a
185 solvent gradient from neat petroleum ether to 50% AcOEt/petroleum ether, compound **22** was
186 obtained as a yellow solid (171 mg, 84%), m.p. 114 – 116 °C. ¹H NMR (400 MHz, CDCl₃) δ 3.84 – 3.88
187 (m, 4H), 4.01 – 4.04 (m, 4H), 7.50 – 7.57 (m, 3H), 7.59 (s, 1H), 7.63 – 7.66 (m, 1H), 7.94 (dd, *J* = 5.3, 8.4
188 Hz, 2H), 8.21 (dd, *J* = 2.8, 6.7 Hz, 1H), 8.66 (s, 1H) ppm. ¹³C NMR (100.6 MHz, CDCl₃) δ 46.43 (2xCH),
189 66.8 (2xCH), 115.0 (C), 125.1 (CH), 125.2 (CH), 125.2 (CH), 126.5 (CH), 127.1 (CH), 128.3 (CH), 128.5
190 (CH), 129.9 (CH), 130.8 (C), 131.3 (C), 133.8 (C), 147.8 (C), 154.5 (CH), 157.9 (C), 161.8 (C) ppm. HRMS:
191 calcd. for C₂₀H₁₈N₃OS [M+H]⁺ 348.1165, found 348.1166.

192 4-(4-morpholinothieno[3,2-d]pyrimidin-6-yl)benzotrile (22)

193 From compound **6** (100 mg; 0.586 mmol), morpholine (102 mg; 1.172 mmol) followed by
194 Pd(OAc)₂ (13 mg; 0.059 mmol), TTBP · HBF₄ (34 mg; 0.117 mmol), K₂CO₃ (162 mg; 1.172 mmol), 4-
195 bromobenzotrile (213 mg; 1.172 mmol) and after purification by column chromatography using a
196 solvent gradient from neat petroleum ether to 60% AcOEt/petroleum ether, compound **23** was
197 obtained as a yellow solid (104 mg, 55%), m.p. 255 – 257 °C. ¹H NMR (400 MHz, CDCl₃) δ 8.61 (s, 1H),
198 7.83 (d, *J* = 8.6 Hz, 2H), 7.75 (d, *J* = 8.6 Hz, 2H), 7.70 (s, 1H), 4.01 (d, *J* = 5.1 Hz, 4H), 3.89 – 3.86 (m, 4H)
199 ppm. ¹³C NMR (100.6 MHz, CDCl₃) δ 162.0 (C), 157.9 (C), 154.8 (CH), 146.6 (C), 137.1 (C), 132.9 (2xCH),
200 127.0 (2xCH), 122.8 (CH), 118.2 (C), 114.9 (C), 112.9 (C), 66.7 (2xCH), 46.4 (2xCH) ppm. HRMS: calcd.
201 for C₁₇H₁₅N₄OS [M+H]⁺ 323.0961, found 323.0957.

202 N-((3s,5s,7s)-adamantan-1-yl)-6-phenylthieno[3,2-d]pyrimidin-4-amine (23)

203 From compound **6** (100 mg; 0.586 mmol), adamantylamine (177 mg; 1.172 mmol) followed by
204 Pd(OAc)₂ (13 mg; 0.059 mmol), TTBP · HBF₄ (34 mg; 0.117 mmol), K₂CO₃ (162 mg; 1.172 mmol),
205 bromobenzene (184 mg; 1.172 mmol) and after purification by column chromatography using a
206 solvent gradient from neat petroleum ether to 25% AcOEt/petroleum ether, compound **24** was
207 obtained as a yellow solid (142 mg, 67%), m.p. 201 – 203 °C. ¹H NMR (400 MHz, CDCl₃) δ 1.72 – 1.79
208 (m, 6H), 2.22 (d, *J* = 40.6 Hz, 9H), 4.47 (s, 1H), 7.37 – 7.48 (m, 3H), 7.55 (s, 1H), 7.71 (d, *J* = 8.4 Hz, 2H),

209 8.57 (s, 1H) ppm. ¹³C NMR (100.6 MHz, CDCl₃) δ 29.7 (3xCH), 36.4 (3xCH), 42.0 (3xCH), 53.6 (C), 115.3
210 (C), 121.0 (CH), 126.6 (2xCH), 129.1 (2xCH), 129.3 (CH), 133.3 (C), 148.2 (C), 154.8 (CH), 156.5 (C),
211 160.2 (C) ppm. HRMS: calcd. for C₂₂H₂₄N₃S [M+H]⁺ 362.1685, found 362.1684.

212 **General procedure for synthesis of 15 and 24 from 6 (one pot 3 steps “C-2” and “C-3” CH** 213 **activation)**

214 A solution of 4-chlorothieno[3,2-d]pyrimidine (**6**) (100 mg; 0.586 mmol) and morpholine (1.172
215 mmol) was heated at 100 °C in dry toluene, for 20 min. Then, Pd(OAc)₂ (0.059 mmol), TTBP·HBF₄ (
216 0.117 mmol), K₂CO₃ (1.172 mmol) and bromo derivative (1.172 mmol) were added. The reaction
217 mixture was stirred at same temperature for 46h. Then, Pd(OAc)₂ (0.059 mmol), TTBP·HBF₄ (
218 0.117 mmol), K₂CO₃ (1.172 mmol) and bromo derivative (1.172 mmol) were added. The reaction mixture
219 was stirred at 130 °C for 46h. The reaction was followed by TLC. After completion, the mixture was
220 concentrated under vacuum. The solid obtained was purified by column chromatography. The
221 solvent polarity was increased via a gradient from neat petroleum ether to a mixture of
222 AcOEt/petroleum ether.

223 **4-(6,7-diphenylthieno[3,2-d]pyrimidin-4-yl)morpholine (15)**

224 From compound **6** (100 mg; 0.586 mmol), morpholine (102 mg; 1.172 mmol) followed 2 times by
225 Pd(OAc)₂ (13 mg; 0.059 mmol), TTBP · HBF₄ (34 mg; 0.117 mmol), K₂CO₃ (162 mg; 1.172 mmol),
226 bromobenzene (184 mg; 1.172 mmol) and after purification by column chromatography using a
227 solvent gradient from neat petroleum ether to 3% AcOEt/petroleum ether, compound **15** was
228 obtained as a yellow solid (105 mg, 48 %), m.p. 182 – 184 °C. ¹H NMR (400 MHz, CDCl₃) δ 3.82 – 3.85
229 (m, 4H), 3.97 – 4.00 (m, 4H), 7.23 – 7.37 (m, 10H), 8.64 (s, 1H) ppm. ¹³C NMR (100.6 MHz, CDCl₃) δ 46.5
230 (2xCH), 66.8 (2xCH), 114.4 (C), 127.7 (CH), 128.5 (2xCH), 128.7 (2xCH), 128.8 (CH), 129.5 (2xCH),
231 130.7 (2xCH), 133.1 (C), 133.6 (2xC), 145.0 (C), 154.7 (CH), 158.0 (C), 161.0 (C) ppm. HRMS: calcd. for
232 C₂₂H₂₀N₃OS [M+H]⁺ 374.1322, found 374.1320.

233 **4-(4-morpholino-6-phenylthieno[3,2-d]pyrimidin-7-yl)benzotrile (24)**

234 From compound **6** (100 mg; 0.586 mmol), morpholine (102 mg; 1.172 mmol) followed 2 times by
235 Pd(OAc)₂ (13 mg; 0.059 mmol), TTBP · HBF₄ (34 mg; 0.117 mmol), K₂CO₃ (162 mg; 1.172 mmol),
236 bromobenzene (184 mg; 1.172 mmol) or 4-bromobenzotrile (213 mg; 1.172 mmol) and after
237 purification by column chromatography using a solvent gradient from neat petroleum ether to 9%
238 AcOEt/petroleum ether, compound **25** was obtained as a yellow solid (84 mg, 36%), m.p. 227 – 229
239 °C. ¹H NMR (400 MHz, CDCl₃) δ 3.87 – 3.90 (m, 4H), 4.02 – 4.05 (m, 4H), 7.28 – 7.40 (m, 5H), 7.53 (d, *J*
240 = 8.5 Hz, 2H), 7.65 (d, *J* = 8.5 Hz, 2H), 8.63 (s, 1H) ppm. ¹³C NMR (100.6 MHz, CDCl₃) δ 46.5 (2xCH),
241 66.8 (2xCH), 111.3 (C), 114.5 (C), 118.9 (C), 129.0 (2xCH), 129.4 (CH), 129.5 (2xCH), 131.6 (2xCH), 160.3
242 (C), 132.1 (2xCH), 132.3 (C), 138.6 (C), 146.6 (C), 154.8 (CH), 158.0 (C) ppm. HRMS: calcd. for
243 C₂₃H₁₉N₄OS [M+H]⁺ 399.1274, found 399.1271.

244 **General procedure for synthesis of 25-29 from 2**

245 A solution of **2** (50 mg; 0.237 mmol), Pd(OAc)₂ (0.024 mmol), TTBP · HBF₄ (0.047 mmol), K₂CO₃
246 (0.473 mmol) and bromo derivative (0.473 mmol) was heated at 130 °C in dry toluene, for 46h. The
247 reaction was followed by TLC. After completion, the mixture was concentrated under vacuum. The
248 solid obtained was purified by column chromatography. The solvent polarity was increased via a
249 gradient from neat petroleum ether to a mixture of AcOEt/petroleum ether.

250 **2,3-diphenylthieno[3,2-b]pyridine (25) [11]**

251 From compound **2** (50 mg; 0.237 mmol), Pd(OAc)₂ (5 mg; 0.024 mmol), TTBP · HBF₄ (14 mg; 0.047
252 mmol), K₂CO₃ (65 mg; 0.473 mmol), bromobenzene (74 mg; 0.473 mmol) and after purification by
253 column chromatography using a solvent gradient from neat petroleum ether to 4% AcOEt/petroleum
254 ether, compound **26** was obtained as a white solid (62 mg, 91%), m.p. 139 – 141 °C. ¹H NMR (400
255 MHz, CDCl₃) δ 7.27-7.45 (m, 11H), 8.21 (dd, *J* = 1.6, 8.1 Hz, 1H), 8.73 (dd, *J* = 1.6, 4.6 Hz, 1H) ppm. ¹³C
256 NMR (100.6 MHz, CDCl₃) δ 118.9 (CH), 127.6 (CH), 128.4 (CH), 128.4 (2xCH), 128.5 (2xCH), 128.6
257 (2xCH), 129.9 (CH), 130.8 (2xCH), 133.2 (C), 133.6 (C), 134.1 (C), 134.2 (C), 143.7 (C), 147.6 (CH), 155.5
258 (C) ppm.

259 **2-phenyl-3-(p-tolyl)thieno[3,2-b]pyridine (26)** [11]

260 From compound **2** (50 mg; 0.237 mmol), Pd(OAc)₂ (5 mg; 0.024 mmol), TTBP · HBF₄ (14 mg; 0.047
261 mmol), K₂CO₃ (65 mg; 0.473 mmol), 4-bromotoluene (81 mg; 0.473 mmol) and after purification by
262 column chromatography using a solvent gradient from neat petroleum ether to 3% AcOEt/petroleum
263 ether, compound **28** was obtained as a white solid (46 mg, 65%), m.p. 138 – 140 °C. ¹H NMR (400
264 MHz, CDCl₃) δ 2.38 (s, 3H), 7.20-7.41 (m, 10H), 8.18 (dd, *J* = 1.6, 8.1 Hz, 1H), 8.71 (dd, *J* = 1.6, 4.6 Hz,
265 1H) ppm. ¹³C NMR (100.6 MHz, CDCl₃) δ 21.4 (CH), 118.8 (CH), 128.3 (CH), 128.5 (2xCH), 129.2
266 (2xCH), 129.5 (2xCH), 129.8 (CH), 130.6 (2xCH), 131.2 (C), 133.1 (C), 133.6 (C), 134.3 (C), 137.2 (C),
267 143.2 (C), 147.5 (CH), 155.7 (C) ppm.

268 **methyl 4-(2-phenylthieno[3,2-b]pyridin-3-yl)benzoate (27)**

269 From compound **2** (50 mg; 0.237 mmol), Pd(OAc)₂ (5 mg; 0.024 mmol), TTBP · HBF₄ (14 mg; 0.047
270 mmol), K₂CO₃ (65 mg; 0.473 mmol), methyl 4-bromobenzoate (102 mg; 0.473 mmol) and after
271 purification by column chromatography using a solvent gradient from neat petroleum ether to 3%
272 AcOEt/petroleum ether, compound **29** was obtained as a white solid (73 mg, 89%), m.p. 173 – 175
273 °C. ¹H NMR (400 MHz, CDCl₃) δ 3.92 (s, 3H), 7.32 (ddt, *J* = 4.4, 8.1, 12.3 Hz, 6H), 7.53 – 7.57 (m, 2H),
274 8.04 – 8.08 (m, 2H), 8.20 (dd, *J* = 1.5, 8.1 Hz, 1H), 8.72 (dd, *J* = 1.5, 4.6 Hz, 1H) ppm. ¹³C NMR (100.6
275 MHz, CDCl₃) δ 52.1 (CH), 119.1 (CH), 128.7 (CH), 128.7 (2xCH), 129.0 (C), 129.6 (2xCH), 129.7 (2xCH),
276 130.0 (CH), 130.9 (2xCH), 132.4 (C), 133.3 (C), 133.7 (C), 139.2 (C), 144.8 (C), 147.7 (CH), 155.0 (C),
277 167.1 (C) ppm. HRMS: calcd. for C₂₁H₁₆NO₂S [M+H]⁺ 346.0896, found 346.0903.

278 **3-(4-ethylphenyl)-2-phenylthieno[3,2-b]pyridine (28)**

279 From compound **2** (50 mg; 0.237 mmol), Pd(OAc)₂ (5 mg; 0.024 mmol), TTBP · HBF₄ (14 mg; 0.047
280 mmol), K₂CO₃ (65 mg; 0.473 mmol), 1-bromo-4-ethylbenzene (87 mg; 0.473 mmol) and after
281 purification by column chromatography using a solvent gradient from neat petroleum ether to 2%
282 AcOEt/petroleum ether, compound **30** was obtained as a white solid (31 mg, 41%), m.p. 118 – 120
283 °C. ¹H NMR (400 MHz, CDCl₃) δ 1.27 (t, *J* = 7.6 Hz, 3H), 2.68 (q, *J* = 7.6 Hz, 2H), 7.21 – 7.24 (m, 2H),
284 7.26 – 7.32 (m, 4H), 7.34 – 7.41 (m, 4H), 8.18 (dd, *J* = 1.5, 8.1 Hz, 1H), 8.72 (dd, *J* = 1.5, 4.6 Hz, 1H) ppm.
285 ¹³C NMR (100.6 MHz, CDCl₃) δ 15.3 (CH), 28.7 (CH), 118.8 (CH), 128.0 (2xCH), 128.3 (CH), 128.5
286 (2xCH), 129.6 (2xCH), 129.9 (CH), 130.6 (2xCH), 131.4 (C), 133.2 (C), 133.6 (C), 134.3 (C), 143.3 (C),
287 143.4 (C), 147.5 (CH), 155.6 (C) ppm. HRMS: calcd. for C₂₁H₁₈NS [M+H]⁺ 316.1154, found 316.1156.

288 **4-(2-phenylthieno[3,2-b]pyridin-3-yl)benzotrile (29)** [11]

289 From compound **2** (50 mg; 0.237 mmol), Pd(OAc)₂ (5 mg; 0.024 mmol), TTBP · HBF₄ (14 mg; 0.047
290 mmol), K₂CO₃ (65 mg; 0.473 mmol), 4-bromobenzotrile (86 mg; 0.473 mmol) and after purification
291 by column chromatography using a solvent gradient from neat petroleum ether to 10%
292 AcOEt/petroleum ether, compound **31** was obtained as a white solid (62 mg, 84%), m.p. 182-184 °C.
293 ¹H NMR (400 MHz, CDCl₃) δ 7.30-7.36 (m, 6H), 7.59 (d, *J* = 8.7 Hz, 2H), 7.69 (d, *J* = 8.0 Hz, 2H), 8.22
294 (dd, *J* = 1.5, 8.1 Hz, 1H), 8.72 (dd, *J* = 1.5, 4.6 Hz, 1H) ppm. ¹³C NMR (100.6 MHz, CDCl₃) δ 111.1 (C),

295 119.0 (C), 119.3 (CH), 128.9 (2xCH), 129.0 (CH), 129.6 (2xCH), 130.2 (CH), 131.3 (C), 131.6 (2xCH),
296 132.1 (2xCH), 133.3 (C), 139.2 (C), 145.5 (C), 147.7 (CH), 154.6 (C) ppm.

297 **General procedure for synthesis of 30-32 from 4**

298 A solution of **4** (50 mg; 0.235 mmol), Pd(OAc)₂ (0.024 mmol), TTBP · HBF₄ (0.047 mmol), K₂CO₃
299 (0.470 mmol) and bromo derivative (0.470 mmol) was heated at 130 °C in dry toluene, for 46h. The
300 reaction was followed by TLC. After completion, the mixture was concentrated under vacuum. The
301 solid obtained was purified by column chromatography. The solvent polarity was increased via a
302 gradient from neat petroleum ether to a mixture of AcOEt/petroleum ether.

303 **6,7-diphenylthieno[2,3-b]pyrazine (30) [11]**

304 From compound **4** (50 mg; 0.235 mmol), Pd(OAc)₂ (5 mg; 0.024 mmol), TTBP · HBF₄ (14 mg; 0.047
305 mmol), K₂CO₃ (65 mg; 0.470 mmol), bromobenzene (74 mg; 0.470 mmol) and after purification by
306 column chromatography using a solvent gradient from neat petroleum ether to 9% AcOEt/petroleum
307 ether, compound **32** was obtained as a white solid (32 mg, 47%), m.p. 155-157 °C. ¹H NMR (400
308 MHz, CDCl₃) δ 7.35-7.45 (m, 10H), 8.52 (d, *J* = 2.4 Hz, 1H), 8.68 (d, *J* = 2.4 Hz, 1H) ppm. ¹³C NMR (100.6
309 MHz, CDCl₃) δ 127.9 (CH), 128.6 (2xCH), 128.7 (2xCH), 128.9 (CH), 129.7 (2xCH), 130.6 (2xCH), 131.2
310 (C), 133.2 (C), 133.5 (C), 140.3 (CH), 142.0 (CH), 144.6 (C), 149.8 (C), 155.6 (C) ppm.

311 **6-phenyl-7-(p-tolyl)thieno[2,3-b]pyrazine (31) [11]**

312 From compound **4** (50 mg; 0.235 mmol), Pd(OAc)₂ (5 mg; 0.024 mmol), TTBP · HBF₄ (14 mg; 0.047
313 mmol), K₂CO₃ (65 mg; 0.470 mmol), 4-bromotoluene (80 mg; 0.470 mmol) and after purification by
314 column chromatography using a solvent gradient from neat petroleum ether to 3% AcOEt/petroleum
315 ether, compound **33** was obtained as a white solid (22 mg, 31%), m.p. 172-174 °C. ¹H NMR (400
316 MHz, CDCl₃) δ 2.39 (s, 3H), 7.22 (d, *J* = 8.0 Hz, 2H), 7.31-7.34 (m, 5H), 7.42-7.44 (m, 2H), 8.49 (d, *J* = 2.4
317 Hz, 1H), 8.65 (d, *J* = 2.4 Hz, 1H) ppm. ¹³C NMR (100.6 MHz, CDCl₃) δ 21.4 (CH), 128.7 (2xCH), 128.8
318 (CH), 129.3 (2xCH), 129.6 (2xCH), 130.2 (C), 130.4 (2xCH), 131.2 (C), 133.6 (C), 137.7 (C), 140.2 (CH),
319 142.0 (CH), 144.1 (C), 150.0 (C), 155.6 (C) ppm.

320 **4-(6-phenylthieno[2,3-b]pyrazin-7-yl)benzotrile (32) [11]**

321 From compound **4** (50 mg; 0.235 mmol), Pd(OAc)₂ (5 mg; 0.024 mmol), TTBP · HBF₄ (14 mg; 0.047
322 mmol), K₂CO₃ (65 mg; 0.470 mmol), 4-bromobenzotrile (86 mg; 0.470 mmol) and after purification
323 by column chromatography using a solvent gradient from neat petroleum ether to 5%
324 AcOEt/petroleum ether, compound **34** was obtained as a white solid (28 mg, 38%), m.p. 219-221 °C.
325 ¹H NMR (400 MHz, CDCl₃) δ 7.36-7.40 (m, 5H), 7.57 (d, *J* = 8 Hz, 2H), 7.70 (d, *J* = 8 Hz, 2H), 8.54 (d, *J*
326 = 2.4 Hz, 1H), 8.66 (d, *J* = 2.4 Hz, 1H) ppm. ¹³C NMR (100.6 MHz, CDCl₃) δ 111.5 (C), 118.8 (C), 128.9
327 (C), 129.1 (2xCH), 129.5 (CH), 129.7 (2xCH), 131.4 (2xCH), 132.2 (2xCH), 132.7 (C), 138.0 (C), 140.8
328 (CH), 142.1 (CH), 146.4 (C), 149.0 (C), 155.6 (C) ppm.


329

330 1.3. ¹H NMR, ¹³C NMR and ¹⁹F NMR Spectra of all Products


331

332

4-(thieno[3,2-d]pyrimidin-4-yl)morpholine (7)




333




334

335

N,N-dibutylthieno[3,2-d]pyrimidin-4-amine (8)


336




337

338

4-(piperidin-1-yl)thieno[3,2-d]pyrimidine (9)



339




340


341

342

N-(2-(trifluoromethyl)phenyl)thieno[3,2-d]pyrimidin-4-amine (10)




343



344

345



346

347

348

349

350

351

352

353

354

355

356


357

358

359

360


N-(4-methoxyphenyl)thieno[3,2-d]pyrimidin-4-amine (11)



361


362

363




364

methyl 4-(thieno[3,2-d]pyrimidin-4-ylamino)benzoate (12)



365




366


367

368

N-((3s,5s,7s)-adamantan-1-yl)thieno[3,2-d]pyrimidin-4-amine (13)




369




370

371

4-(6-phenylthieno[3,2-d]pyrimidin-4-yl)morpholine (14)




372



373

374


4-(6-(p-tolyl)thieno[3,2-d]pyrimidin-4-yl)morpholine (16)



375


376

377




378

4-(6-(3,4,5-trimethoxyphenyl)thieno[3,2-d]pyrimidin-4-yl)morpholine (17)




379




380

381

methyl 4-(4-morpholinothieno[3,2-d]pyrimidin-6-yl)benzoate (18)




382




383

384

4-(6-(4-ethylphenyl)thieno[3,2-d]pyrimidin-4-yl)morpholine (19)



385




386

387


388

4-(6-(benzo[b]thiophen-2-yl)thieno[3,2-d]pyrimidin-4-yl)morpholine (20)




389

390




391

4-(6-(naphthalen-1-yl)thieno[3,2-d]pyrimidin-4-yl)morpholine (21)




392




393

394

4-(4-morpholinothieno[3,2-d]pyrimidin-6-yl)benzotrile (22)




395




396

397

N-((3s,5s,7s)-adamantan-1-yl)-6-phenylthieno[3,2-d]pyrimidin-4-amine (23)




398




399

400

4-(6,7-diphenylthieno[3,2-d]pyrimidin-4-yl)morpholine (15)



401




402


403

404

4-(4-morpholino-6-phenylthieno[3,2-d]pyrimidin-7-yl)benzotrile (24)




405




406

407

2,3-diphenylthieno[3,2-b]pyridine (25)




408




409

410

2-phenyl-3-(p-tolyl)thieno[3,2-b]pyridine (26)



411




412


413

417

3-(4-ethylphenyl)-2-phenylthieno[3,2-b]pyridine (28)




418




419

420

4-(2-phenylthieno[3,2-b]pyridin-3-yl)benzonitrile (29)




421




422

423

6,7-diphenylthieno[2,3-b]pyrazine (30)



424




425


426

427

6-phenyl-7-(p-tolyl)thieno[2,3-b]pyrazine (31)




428




429

430

4-(6-phenylthieno[2,3-b]pyrazin-7-yl)benzotrile (32)




431



432

433 1.4. References

- 434 30. Barelier, S.; Eidam, O.; Fish, I.; Hollander, J.; Figaroa, F.; Nachane, R.; Irwin, J.J.; Shoichet, B.K.; Siegal,
435 G. Increasing Chemical Space Coverage by Combining Empirical and Computational Fragment
436 Screens ACS Chem. Biol. **2014**, *9*, 7, 1528-1535, doi:10.1021/cb5001636.
- 437 31. Kemnitzer, W.; Sirisoma, N.; May, C.; Tseng, B.; Drewe, J.; Cai, S.X. Discovery of 4-anilino-N-
438 methylthieno[3,2-d]pyrimidines and 4-anilino-N-methylthieno[2,3-d]pyrimidines as potent
439 apoptosis inducers *Bioorganic Med. Chem. Lett* **2009**, *19*, 13, 3536-3540, doi:10.1016/j.bmcl.2009.04.145.
440
441



© 2018 by the authors. Submitted for possible open access publication under the terms and conditions of the Creative Commons Attribution (CC BY) license (<http://creativecommons.org/licenses/by/4.0/>).